A recent conversation with Dr. John Farley, director of the U.S. FDA’s Office of Infectious Diseases, provided insights regarding Paxlovid, the preferred oral therapy for managing non-hospitalized adults with COVID-19.
The antiviral Paxlovid reduces the risk of hospitalization and death for patients with mild-to-moderate COVID-19 at high risk of disease progression.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
